果旭阿汤中土木香内酯和异土木香内酯的含量测定

［摘要］目的建立同时测定藏药果旭阿汤中土木香内酯和异土木香内酯含量的方法。方法通过优化提取方法,用气相色谱（GC）法同时测定藏药果旭阿汤中藏木香有效成分土木香内酯和异土木香内酯的含量。结果土木香内酯和异土木香内酯均在0.1～1.0 mg•mL-1 (n=5）范围内呈良好线性关系。土木香内酯回收率为97.25% (n=6),RSD=0.93%;异土木香内酯回收率为97.42% (n=6), RSD=0.90%。结论该方法可用于藏药果旭阿汤中土木香内酯和异土木香内酯的含量同时快速、准确测定。     

ICP—MS法测定藏药智托洁白丸中微量元素

目的：建立藏药智托洁白丸中微量元素含量的测定方法。方法：样品经微波消解后,以铑为内标,用电感耦合等离子体质谱（ICP—MS）测定样品中Cr、Mn、Ni、Co、Cu、Zn、As、Pb、Fe、Se等10种微量元素的含量。结果：该方法对各元素的检出限为0．003-0．093μg·g^-1,加标回收率在96-106％之间,国家标准物质茶标（GBW07404）和杨树叶（GBW07405）的测定值与标准值基本吻合。结论：方法快速、准确、灵敏度高,可以用于测定智托洁白丸中微量元素的含量。     

三维适形放疗结合252锎中子腔内后装照射治疗中晚期食管癌的临床研究

目的:探讨三维适形放疗结合锎(252Cf)中子腔内后装照射治疗中晚期食管癌的疗效、不良反应及晚期并发症。方法:92例中晚期食管癌患者全部采用三维适形放疗结合锎(252Cf)中子腔内后装照射治疗。三维适形放疗总剂量为45Gy-54Gy,分25-30次,5-6周完成;腔内照射3-4Gy/次,1次/周,共2-4次,总吸收剂量10Gy-16Gy。结果:治疗结束3个月进食梗阻缓解率为95%。近期疗效:完全缓解(CR)27%,部分缓解(PR)69.6%。1、2、3年局部控制率分别为82%、51%、32%;1、2、3年生存率分别为:78%、35%、18%;急性放射性食管炎发生率为54%;晚期食管狭窄发生率9%;食管穿孔发生率2%。结论:中晚期食管癌采用三维适形放疗结合锎(252Cf)中子腔内后装照射能够迅速而持久地缓解进食梗阻症状,提高局部控制率及生活质量,近期疗效显著,放疗不良反应未见明显增加。     

Human fibrinogen polymorphic site analysis by restriction endonuclease digestion and allele-specific polymerase chain reaction amplification: identification of polymorphisms at positions A alpha 312 and B beta 448

In the fibrinogen molecule, a total of seven sites have been tentatively identified as polymorphic; however, disagreements about these sites have been observed among the various protein and DNA sequence data published. To allow examination of the potential polymorphic sites at the DNA level, human genomic DNA samples were prepared from 110 unrelated, healthy individuals. Either allele- specific polymerase chain reaction (ASPCR) amplification or PCR amplification followed by restriction endonuclease digestion was used to detect the presence of possible polymorphisms. Two polymorphic sites were confirmed, one at A alpha 312 (Thr/Ala) by RsaI restriction analysis, and a second at B beta 448 (Arg/Lys) by MnlI restriction analysis. Mendelian inheritance of both polymorphisms was demonstrated and allele frequencies were estimated as 0.76/0.24 and 0.85/0.15 for the A alpha 312 and B beta 448 sites, respectively. The sites at A alpha 47, A alpha 296, B beta 162, B beta 296, and gamma 88 showed no evidence of variation in any of our samples. The amino acid polymorphisms at A alpha 312 and B beta 448 reflect conservative residue changes with unknown effects on fibrinogen structure or function. An additional, previously unrecognized DNA sequence variant was detected in a single individual in the second intron of the A alpha chain using HinfI restriction analysis.